Allogeneic bone marrow transplantation (BMT) is an effective therapy for a variety of malignancies and blood disorders, but rarely serves as a frontline treatment because of numerous, potential complications. Important and frequent complications relate to the profound immunosuppression that inevitably occurs during the first several months following treatment. To better elucidate and subsequently improve immune reconstitution, we examined T and B cell subsets among 43 pediatric BMT recipients in a retrospective study. We found that the relative numbers of T cells and B cells (T:B ratios) were discordant and highly variable among patients at day ෂ100 after BMT. Further investigation of BMT parameters identified a strong correlation between T:B ratios and immunosuppressive drug treatments, providing an explanation for variable lymphocyte reconstitution profiles. Results suggest that: (1) immunosuppressive therapy inhibits B cell expansion more strongly than T cell expansion following BMT; (2) WBC and absolute lymphocyte counts fail to reveal profound B cell immunodeficiencies in some BMT patients; and (3) routine analyses of T:B ratios serve to identify patients warranting close follow-up and extended supportive immunotherapy. including influenza, parainfluenza viruses and adenoviruses also contribute to substantial disease following BMT.
including influenza, parainfluenza viruses and adenoviruses also contribute to substantial disease following BMT. [3] [4] [5] Several laboratories have sought to define correlations between transplant conditions and lymphocyte development using techniques such as sheep-rosetting, T cell proliferation studies and flow cytometry. [6] [7] [8] [9] [10] Results have varied between studies, depending on the precise patient populations and transplantation regimens under investigation, but there has been no clear explanation for variability.
To improve our understanding of immune reconstitution, we conducted a comprehensive, retrospective study of pediatric patients enrolled in an allogeneic BMT protocol. We assessed patients receiving matched-unrelated or mismatched-related transplants, for whom day ෂ100 immunophenotyping data were available. As with previous studies, T and B cell profiles were highly variable. Further investigation of BMT parameters revealed a significant correlation between the duration of immunosuppressive drug treatments and T:B ratios, providing an explanation for variable T and B cell profiles. Results also showed that absolute lymphocyte counts failed to predict T:B subset distributions, underscoring the importance of routine immunophenotyping to identify profound delays in B cell recovery.
Materials and methods

Patient population
This report describes a retrospective study of B cell and T cell reconstitution among patients who received an allogeneic bone marrow transplant at St Jude Children's Research Hospital (SJCRH) from a matched-unrelated or mismatched-related donor between the years 1993 and 1998. T:B ratios were examined on day ෂ100 (day 75 to day 125) post BMT as an early assessment of lymphocyte reconstitution. Evaluable patients were those for whom T:B ratios were available at day ෂ100 and who exhibited at least 15% CD19
+ or CD3 + cells in the lymphocyte population. Of the 43 evaluable patients (among 254 total patients), 17 had acute myeloblastic leukemia (AML), nine had chronic myelogenous leukemia (CML), eight had acute lymphoblastic leukemia (ALL), five had myelodysplastic syndrome (MDS), two had non-Hodgkin's lymphoma (NHL), one had severe aplastic anemia (AA) and one had Hurler's syndrome (HS). Patient characteristics are listed in Table 1 .
Transplant regimen and supportive therapy
The conditioning regimen consisted of cytosine arabinoside (3 g/m 2 i.v. administered every 12 h from day −8 to day −5), cyclophosphamide (45 mg/kg/day i.v. administered from day −7 to day −6) and fractionated TBI (14 Gy in eight divided doses delivered over 4 consecutive days from day −4 to day −1) as previously described. 5 Donor marrow was infused on day 0. CD34 + cell content of infused marrow ranged from 0.2 × 10 5 to 86 × 10 5 cells/kg and the T cell content ranged from 0.5 × 10 5 to 34.1 × 10 5 cells/kg. The day of engraftment (ANC у500 cells/mm 3 ) was sig- nificantly associated with CD34 dose (P = 0.0058), but not with T cell dose (P = 0.23).
Graft-versus-host disease (GVHD) prophylaxis included in vitro T cell depletion (approximately 1.5 log depletion) of the graft using anti-CD6 and anti-CD8 monoclonal antibodies and rabbit complement as previously described. 5 Cyclosporine was administered intravenously starting on day −2 (dose adjusted to achieve levels of 150-250 ng/ml) and changed to oral cyclosporine when tolerated. For patients without GVHD, cyclosporine was tapered starting at day ෂ45.
Upon engraftment, antimicrobial prophylaxis was initiated for Pneumocystis carinii (co-trimoxazole, when ANC у500 cells/mm 3 ) and, when indicated, for CMV (ganciclovir, when ANC у1000 cells/mm Intravenous immunoglobulin (500 mg/kg) was initiated on day +2, administered weekly until day +90 and monthly until day +365. Broad-spectrum antibiotics were started for fever and amphotericin was added for fungal disease or persistent fever. Patients received prednisone or methylprednisolone (ෂ1-2 mg/kg/day) for grade 1 or 2 GVHD. 5 Persistent or worsening GVHD was treated with increased steroids (5-10 mg/kg/day), and the ABX-CBL-1 monoclonal antibody (Abgenix, Fremont, CA, USA, specific for an antigen shared by activated T cells, B cells, and natural killer cells 11 ) was used in patients who failed to improve following 5 days of high-dose steroids. GVHD prophylaxis/treatment was administered with considerations given to the number of T cells in the graft, the response to treatment, and evidence of intercurrent infection. Clinical protocols were reviewed by the Institutional Review Board of SJCRH. Informed consent was obtained from the guardian or parent of each child.
Lymphocyte analyses
During routine patient visits, complete blood cell counts (CBC) and lymphocyte analyses were performed. Lymphocyte subpopulations were isolated by density centrifugation and analyzed by flow cytometry (FACScan; Becton Dickinson, Mountain View, CA, USA). Fluorescent antibodies were specific for CD3 and CD19 (Dako Corporation, Carpinteria, CA, USA). Reagents were utilized in conjunction with isotype-matched controls as recommended by the manufacturers. Cells were stained in the presence of normal rabbit IgG (Dako) as a blocking reagent. The lymphocyte gate was selected by forward and side scatter parameters, and confirmed by Leucogate (CD45, CD14; Dako) staining. Results were expressed as a percentage of lymphocytes.
Statistical analyses
The primary focus of this study was to assess the association of T:B ratio (dependent variable; Y) with several factors of interest (independent variables; x) such as WBC, lymphocyte percentages, duration of prednisone usage, duration of cyclosporine usage, etc. The least absolute deviations (LAD) approach 12 was used to assess the association between the dependent and independent variables. S-Plus was used to obtain the plots. The LAD model testing was conducted using FORTRAN and routine DRLLP from IMSL library. Thus, for each independent variable, we considered the model of the type Y = ␤ 0 + ␤ 1 x and assessed if the P value corresponding to the test of ␤ 1 = 0 was significant at level ␣ = 0.05. In a similar manner we assessed the association between total B cells and the independent variables mentioned above, and repeated the same analyses for total T cells. The Cox proportional hazard model was used to examine the correlation of T:B ratios and overall survival.
Bone Marrow Transplantation
Results
High T:B ratios in a subset of BMT patients reflects lagging B vs T cell reconstitution
A retrospective study of T and B cell reconstitution was performed by assembling data from patients who received matched-unrelated or mismatched-related BMT (see Materials and methods section and Table 1 for patient characteristics). T and B cell percentages were determined by FACS analyses of lymphocytes among patient PBMC at day ෂ100. T:B ratios were then calculated (%T divided by %B) and patients were arranged in rank order (Tables  1 and 2 ). As shown in Table 2 , results demonstrated a wide variation among patients for T and B cell reconstitution, with T:B ratios ranging from 0.25 to 146. In many patients, both B cell and T cell subsets were well represented by day ෂ100 (eg patients at the top of the table). In contrast, numerous patients demonstrated superior T cell compared to B cell reconstitution (eg patients at the bottom of the table). Approximately one quarter of the BMT patients demonstrated a T:B ratio Ͼ20 at day ෂ100, reflecting a substantial lag in B cell reconstitution.
An analysis of numerous patient parameters was performed to reveal correlations that might explain the differences in T:B ratios among patients. We first questioned whether WBC counts or lymphocyte percentages could be used to predict or reflect T:B ratios. We identified a correlation between lymphocyte percentages and absolute T and B cell numbers, but neither WBC nor lymphocyte percentages correlated with T:B ratios (Tables 2 and 3) . For this reason, some patients (eg patients 42 and 43) with satisfactory WBC and lymphocyte numbers displayed extremely high T:B ratios. Thus, adequate WBC and lymphocyte percentages could mask profound B cell deficiencies following BMT.
Variables relating to bone marrow graft composition (CD34 or T cell dose) were also tested for correlations with T:B ratio. As shown in Table 3 , no association of CD34 cell or T cell dose with T:B ratio could be demonstrated.
Extended corticosteroid treatment post BMT correlates with lagging B cell vs T cell reconstitution
To examine the effects of immunosuppression on T and B cell reconstitution, we tabulated steroid (prednisone or methylprednisolone) and cyclosporine usage among patients during the first 100 days post BMT. A striking correlation was evident between the duration of steroid use and relative T and B lymphocyte reconstitution (P Ͻ 0.001, Figure 1 , upper panel, Tables 3 and 4 ). Eleven of the 43 patients had T:B ratios of у20, and all but one such patient (91%) had received more than 40 days of steroid treatment. Conversely, among the remaining 32 patients with T:B ratios Ͻ20, only six (19%) had received more than 40 days of steroid treatment. Analyses of steroid doses (Tables 3  and 4 ) demonstrated that T:B ratios were affected by the duration of immunotherapy at both high-and low-dose levels.
Per protocol, cyclosporine GVHD prophylaxis was generally not tapered until any concomitant prednisone or 80  24  44  9  5  2400  10  106  22  25  33  7  5  7300  21  506  107  26  32  7  5  7100  12  273  60  27  59  6  10  7000  16  661  67  28  69  7  10  3800  20  524  53  29  73  7  10  5200  62  2354  226  30  20  2  10  1000  27  54  5  31  15  1  15  4300  32  206  14  32  54  3  18  2300  23  286  16  33  42  2  21  1000  30  126  6  34  45  2  23  6800  13  398  18  35  78  3  26  700  88  480  18  36  31  1  31  4000  25  310  10  37  32  1  32  1600  23  118  4  38  40  1  40  2800  3  34  1  39  44  1  44  27 500  1  121  3  40  29  0.5  58  2600  32  241  4  41  69  1  69  3000  11  228  3  42  79  1  79  2200  22  382  5  43  73  0.5  146  2900  25  529  4 The percentages of lymphocytes expressing CD3 (T cells) and CD19 (B cells) in peripheral blood are shown at the day ෂ100 time point. The T:B ratio (CD3 %/CD19 %) is also shown. Ratios were rounded to the nearest whole number except for values less than one, that were rounded to the nearest quarter. WBC (×10 6 /l), lymphocyte percents (lymph %) and absolute B and T cell numbers (×10 6 /l) in peripheral blood are also shown for the day ෂ100 time point. Cell numbers were rounded to the nearest thousand for WBC and nearest whole number for B and T cells. methylprednisolone treatment was completed. Thus most patients treated for long periods with steroids received concomitant therapeutic cyclosporine (Tables 3 and 4) . Accordingly, a correlation between T:B ratios and the duration of cyclosporine treatment at therapeutic levels was evident (P Ͻ 0.001, Figure 1 , lower panel), paralleling the T:B ratio correlation with steroid treatments. Results were also examined by comparing absolute T cell and B cell counts with drug usage. B cell counts, but not T cell counts, correlated (inversely) with drug usage (Figure 2 , Tables 2  and 3 ).
There was an overall association between T:B ratios and GVHD (P = 0.036, Table 4 ), but the association was weaker than that between T:B ratios and immunosuppressive drug usage (P Ͻ 0.001). The three variables (T:B ratio, GVHD and drug usage) were intertwined, given that the extension of drug usage was routinely prescribed as treatment for GVHD.
Relatively poor treatment outcome among patients with high T:B ratios at day ෂ100
Among the 43 patients monitored in this study, we observed that 11 manifested T:B ratios of у20 on day ෂ100. Four of these patients ultimately died of infectious complications (the only non-relapse-related deaths in the study), and four others died of tumor relapse. This was in marked contrast to the outcome for patients with low T:B ratios (Ͻ1, n = 12), among whom only two deaths occurred, both due to tumor relapse. While deaths were frequent 577 Table 3 Results of LAD model testing Bone Marrow Transplantation among patients with high T:B ratios on day ෂ100, the overall correlation between T:B ratios and survival did not reach statistical significance (P = 0.078) in this study.
Discussion
Lymphocyte reconstitution following allogeneic T celldepleted BMT is of critical importance to patient outcome. This study compared the proportional recovery of T vs B lymphocyte subsets, and investigated factors that could affect T:B ratios. The study revealed substantial differences in T:B ratios (ranging from 0.25 to 146) among BMT recipients. High T:B ratios were not reflected as low WBC counts or lymphopenia. Indeed, adequate WBC and absolute lymphocyte counts masked profound B cell immunodeficiencies in some patients. Based on these results, we encourage the routine analysis of T and B populations in the BMT setting. Unmasking poor B cell recovery may provide early identification of patients warranting close followup and extended supportive immunotherapy.
The spectrum of B cell responses observed here contrasted with the uniformly poor B cell reconstitution seen following BMT for various genetic immunodeficiencies. 8 In the latter case, B cell deficiencies probably reflected the lack of ablative conditioning, permitting the persistence of competitive, host-derived B cell precursors.
To identify possible factors that may have affected B cell reconstitution in the population studied here, we analyzed individual patient records. Results demonstrated a strong correlation between high T:B ratios and the duration of immunosuppressive therapy. Most patients who received steroids for Ͼ40 days during the first 100 days post BMT exhibited T:B ratios of у20:1. In contrast, the patients in our study who did not receive extensive immunosuppressive therapy generally reconstituted B cells within ෂ100 days. Important to outcome, patients with T:B ratios у20:1 fared worse than patients with ratios approaching normal range: non-relapse-related deaths occurred only among patients who had T:B ratios у20:1 at day ෂ100.
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prednisone is included in treatment regimens for B cell leukemias and lymphomas precisely because of B cell susceptibility to corticosteroids. This effect extends to B cell precursors: animal studies have shown steroid treatments to mediate a 100-fold decrease in bone marrow resident pre-B cell populations, 13 and tissue culture experiments have shown that B cell development requires the removal of corticosteroids.
14 Additionally, the administration of prednisone to healthy adults has been shown to suppress B cell responses for an extended period, but to affect T cells only transiently. 15 A retrospective analysis of previous work supports the cause-effect relationship between steroid treatment and disrupted lymphocyte ratios. 9, 10, 16 As one example, a study of partially mismatched BMT recipients 9 demonstrated effective control of GVHD with a lengthy course of steroids, yet there was a substantial lag in B cell reconstitution. In a separate study, BMT patients who received T cell-depleted allogeneic BMT without immunosuppression recovered B cells before T cells. 10 Despite the fact that the strongest correlation defined by this study was between immunosuppressive drug usage and T:B ratios (P Ͻ 0.001), it could be speculated that GVHD rather than immunosuppressive drug usage was responsible for high T:B numbers. Indeed, the variables of GVHD and immunosuppressive drug usage were intertwined. However, due to the fact that B cells have been shown to be particularly sensitive to steroids in unrelated systems (described above), we suggest that immunosuppressive drugs were primarily responsible for altered T:B ratios after BMT.
What can be done to counter the suppression of B cell development? Clearly, the removal of immunosuppressive drugs in attempts to enhance B cell development cannot be performed without consequence. Striking an appropriate balance between the substantial risks and benefits of immunosuppressive drug usage after BMT has always been extremely difficult. As awareness is heightened regarding the risks of extended drug usage, new strategies for preventing GVHD might be contemplated. One such strategy is to manipulate donor cells in vitro prior to infusion. To this end, we have developed a system ('host-specific T cell depletion', HSTD) which utilizes the fluorescence activated cell sorter to remove host-specific proliferative and cytotoxic cells from donor T cell populations. [17] [18] [19] The substitution of manipulated T cells for unmanipulated T cells in the BMT graft could enhance anti-viral function and engraftment success, but circumvent the substantial risks of GVHD and GVHD prophylaxis.
